[1] WHO．Medicines: medicines for children [EB/OL]．[2016-08-16]．http://www．who．int/maternal child
adolescent/topics/child/zh/．
[2] PENAZZATO M, PALLADINO C, SUGANDHI N, et al．Prioritizing the most needed formulations to accelerate paediatric antiretroviral therapy scale-up [J]．Curr Opin HIV AIDS, 2017, 12(4): 369-376．
[3] PENAZZATO M, LEE J , CAPPARELLI E, et al．Optimizing drugs to reach treatment targets for children and adolescents living with HIV [J]．J Int AIDS Soc, 2015,18(Suppl 6): 20270．
[4] 国务院办公厅．“十二五”期间深化医药卫生体制改革规划暨实施方案[EB/OL]．[2012-03-21]．http://www．gov．cn/zwgk/2012-03/21/content_2096671．htm．
[5] 国务院办公厅．关于完善公立医院药品集中采购工作的指导意见[EB/OL]．[2016-08-25]．http://www．gov．cn/ zhengce/content/ 2015-02/28/content_9502．htm．
[6] 国务院办公厅．中国儿科发展纲要[EB/OL]．[2011-07-30]．http://www．gov．cn/gongbao/content/2011/content_1927200．htm．
[7] 国务院办公厅．关于促进医药产业健康发展的指导意见[EB/OL]．[2016-03-11]．http://www．gov．cn/zhengce/content/2016-03/11/content_5052267．htm．
[8] 国务院办公厅．关于改革完善仿制药供应保障及使用政策的意见[EB/OL]．[2018-04-03]．http://www．gov．cn/xinwen/2018-04/03/content_5279672．htm．
[9] 国家食品药品监督管理总局． 关于深化药品审评审批改革进一步鼓励创新的意见[EB/OL]．[2017-10-08]．http://www．gov．cn/xinwen/2017-10/08/content_5230105．htm．
[10] 药品审评中心．关于临床急需儿科用药申请优先审评审批品种评定基本原则及首批优先审评品种的公告[EB/OL]．[2016-08-30]．http: //www．cde．org．cn/news．do?method=largeInfo&id=313519．
[11] 国务院办公厅． “ 十三五” 国家食品安全规划和“十三五”国家药品安全规划[EB/OL]．[2017-02-21]．http://www．gov．cn/zhengce/content/2017-02/21/content_5169755．htm．
[12] 国家食品药品监督管理总局．关于发布儿科人群药物临床试验技术指导原则的通告(2016年第48号)[EB/OL]．[2016-08-25]．http://www．sda．gov．cn/WS01/CL0087/146408．html．
[13] 国家食品药品监督管理总局．关于鼓励药品创新实行优先审评审批的意见[EB/OL]．[2017-12-28]．http://samr．cfda．gov．cn/WS01/CL0844/220706．html．
[14] 国家卫生和计划生育委员会．关于保障儿科用药的若干意见[EB/OL]．[2014-05-21]．http://www．nhfpc．gov．cn/yaozs/s3581/201405/e51354d631944fa68aac0c4d9585f291．shtml．
[15] 国家卫生和计划生育委员会．关于成立国家卫生计生委儿科用药专家委员会的通知[EB/OL]．[2015-03-12]．http://www．nhfpc．gov．cn/yaozs/s3581/201503/1bd6e7f347b34676bcbccf77fb255bc1．shtml．
[16] FDA．New pediatric labeling information database,June 2018 [EB/OL]．[2018-06-30]．https://www．accessdata．fda．gov/scripts/sda/sdNavigation．cfm?sd=labelingdatabase．
[17] FDA．Reviews of pediatric studies conducted under BPCA and PREA from 2007-2012, December 2017[EB/OL]．[2017-12-18]．https://www．fda．gov/drugs/developmentapprovalprocess/developmentresources/ucm049872．htm．
[18] FDA．Best pharmaceuticals for Children Act and Pediatric Research Equity Act status report to congress, July 2016 [EB/
OL]．[2016-07-05]．https://www．fda．gov/downloads/scienceresearch/specialtopics/pediatrictherapeuticsresearch/ucm509815．pdf．
[19] FDA．Pediatric exclusivity granted, July 2018[EB/OL]．[2018-08-03]．https://www．fda．gov/drugs/
developmentapprovalprocess/developmentresources/ucm050005．htm．
[20] BONATI M, CHOONARA I, HOPPU K, et al．Closing the gap in drug therapy [J]．Lancet, 1999, 353(9164): 1625．
[21] SAINT-RAYMOND A, SEIGNEURET N．Medicines for children: time for Europe to act [J]．Paediatr Perinat Drug Ther, 2005, 6: 142-146．
[22] EMA．EU clinical trials register． Clinical trials [EB/OL]．[2018-07-08]．https://www．clinicaltrialsregister．eu/ctr-search/search．
[23] EMA．10 Years of the EU pediatric regulation． Report from the Commission to the European Parliament and the Council, October 2017 [EB/OL]．[2017-10-26]．https://ec．europa．eu/health/sites/health/files/files/paediatrics/docs/2017_childrensmedicines_report_en．pdf．
[24] Pharmaceuticals and Medical Devices Agency．Pediatric Drugs WG． Pediatric drug development in Japan and International Regulatory Collaboration． 14th DIA Japan Annual Meeting 2017, November 2017 [EB/OL]．[2017-11-12]．http://www．pmda．go．jp/files/000224497．
pdf．
[25] Pharmaceuticals and Medical Devices Agency．Pediatric Drugs WG． Development of pediatric drug in Japan:Regulatory viewpoints．12th Annual Meeting, DIA Japan 2015, November 2015 [EB/OL]．[2015-11-12]．http://www．pmda．go．jp/files/000216529．pdf．